Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Kansas City, KA
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Detroit, MI
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Reno, NV
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lebanon, NH
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Mount Kisco, NY
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Mount Kisco, NY
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New York, NY
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Winston-Salem, NC
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Memphis, TN
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ogden, UT
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Leesburg, VA
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Leesburg, VA
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Kennewick, WA
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Joliet, IL
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
Intratumoral Genetic Therapy for Lung Cancer
Status: Enrolling
Updated:  1/16/2018
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
A Vaccine Trial for Patients With Stage IIIB, IV, or Recurrent Non-Small Cell Lung Cancer
Intratumoral Genetic Therapy for Lung Cancer
Status: Enrolling
Updated: 1/16/2018
VA Greater Los Angeles Healthcare System, West Los Angeles, CA
mi
from
West Los Angeles, CA
Click here to add this to my saved trials
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy
Status: Enrolling
Updated:  1/16/2018
Baylor College of Medicine
mi
from
Houston, TX
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer
A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy
Status: Enrolling
Updated: 1/16/2018
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
Moores University of California San Diego Cancer Center
mi
from
La Jolla, CA
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
Moores University of California San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
University of Chicago
mi
from
Chicago, IL
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
Rhode Island Hospital
mi
from
Providence, RI
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
University of Vermont
mi
from
Burlington, VT
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase I Study of Accelerated Hypofractionated Radiation Therapy With Concomitant Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Status: Enrolling
Updated:  1/17/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy
A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
Status: Enrolling
Updated: 1/17/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
University of California, San Diego Medical Center
mi
from
La Jolla, CA
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
University of California, San Diego Medical Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
UCLA Medical Center
mi
from
Los Angeles, CA
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Sharp Clinical Oncology Research-Sharp Memorial Hospital
mi
from
San Diego, CA
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Sharp Clinical Oncology Research-Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Innovative Clinical Research Institute, LLC
mi
from
Whittier, CA
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
University of Colorado Denver
mi
from
Aurora, CO
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Yale University School of Medicine/Yale Cancer Center
mi
from
New Haven, CT
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Yale University School of Medicine/Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Christiana Hospital
mi
from
Newark, DE
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
University of Chicago
mi
from
Chicago, IL
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
University of Nebraska Medical Center Eppley Cancer Center
mi
from
Omaha, NE
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
University of Nebraska Medical Center Eppley Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Montefiore Medical Center
mi
from
Bronx, NY
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/17/2018
Montefiore Medical Center
mi
from
Bronx, NY
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/17/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials